0001123292-24-000416.txt : 20241227 0001123292-24-000416.hdr.sgml : 20241227 20241227163553 ACCESSION NUMBER: 0001123292-24-000416 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241227 DATE AS OF CHANGE: 20241227 EFFECTIVENESS DATE: 20241227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Salarius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001615219 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 465087339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-533510 FILM NUMBER: 241586073 BUSINESS ADDRESS: STREET 1: 2450 HOLCOMBE BLVD STREET 2: SUITE J-608 CITY: HOUSTON STATE: TX ZIP: 77021 BUSINESS PHONE: 346-772-0346 MAIL ADDRESS: STREET 1: 2450 HOLCOMBE BLVD STREET 2: SUITE J-608 CITY: HOUSTON STATE: TX ZIP: 77021 FORMER COMPANY: FORMER CONFORMED NAME: Flex Pharma, Inc. DATE OF NAME CHANGE: 20140730 D 1 primary_doc.xml X0708 D LIVE 0001615219 Salarius Pharmaceuticals, Inc. 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 832-834-9144 DELAWARE None Flex Pharma, Inc. Corporation true Mark J. Rosenblum 2540 Holcombe Blvd. Houston TX TEXAS 77021 Executive Officer Executive Vice President, Chief Financial Officer David J. Arthur 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Executive Officer Chief Executive Officer, President William McVicar 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Chairman of Board Jonathan Lieber 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Tess Burleson 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Arnold C. Hanish 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Paul Lammers 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Bruce J. McCreedy 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Biotechnology Decline to Disclose 06b false true true true false 0 10000000 0 10000000 false 1 0 true 0 true 0 false Salarius Pharmaceuticals, Inc. Mark J. Rosenblum /s/ Mark J. Rosenblum Chief Financial Officer 2024-12-27